T1	Procedure 535 549	drug injection
T2	Procedure-Name 535 549	drug injection
E1	Procedure:T1 Name:T2 Temporality:E33
T3	Procedure 462 475	contraception
T4	Procedure-Name 462 475	contraception
E3	Procedure:T3 Name:T4
T5	Life-Stage-And-Gender 36 42	female
A1	Life-Stage-And-Gender-Type T5 female
T8	Life-Stage-And-Gender 28 32	Male
A2	Life-Stage-And-Gender-Type T8 male
T9	Condition 813 824	anaphylaxis
T10	Condition-Name 813 824	anaphylaxis
E9	Condition:T9 Name:T10
T11	Procedure 699 710	antibiotics
T12	Procedure-Name 699 710	antibiotics
E11	Procedure:T11 Name:T12
T13	Eq-Operator 52 53	≥
A3	Eq-Operator-Value T13 GTEQ
T15	Eq-Operator 189 190	≥
A5	Eq-Operator-Value T15 GTEQ
T16	Eq-Operator 209 210	≥
A6	Eq-Operator-Value T16 GTEQ
T17	Eq-Operator 233 234	≥
A7	Eq-Operator-Value T17 GTEQ
T18	Eq-Operator 591 592	<
A8	Eq-Operator-Value T18 LT
T19	Eq-Operator 624 630	within
A9	Eq-Operator-Value T19 LTEQ
T20	Eq-Operator 755 761	within
A10	Eq-Operator-Value T20 LTEQ
T22	Eq-Temporal-Unit 134 139	years
A12	Eq-Temporal-Unit-Value T22 year
T23	Eq-Temporal-Unit 508 513	weeks
A13	Eq-Temporal-Unit-Value T23 week
T24	Eq-Unit 596 598	kg
T25	Age 74 77	age
E12	Age:T25 Eq-Comparison:E13
T26	Eq-Value 54 56	12
T28	Eq-Value 132 133	2
T29	Eq-Value 191 193	16
T30	Eq-Value 211 212	3
T31	Eq-Value 235 237	10
T32	Eq-Value 505 507	12
T33	Eq-Value 593 595	30
T34	Eq-Value 631 632	1
T35	Eq-Value 762 763	1
T36	Eq-Comparison 52 70	≥ 12 to < 18 years
E13	Eq-Comparison:T36 Operator:T13 Value:T26 Temporal-Unit:T27 Value2:T21 Operator2:T14
T38	Eq-Comparison 189 193	≥ 16
E15	Eq-Comparison:T38 Operator:T15 Value:T29
T39	Eq-Comparison 209 212	≥ 3
E16	Eq-Comparison:T39 Operator:T16 Value:T30
T40	Eq-Comparison 233 265	≥ 10% of Body Surface Area (BSA)
E17	Eq-Comparison:T40 Operator:T17 Value:T31 Unit:T59 Unit2:T60 Unit3:T61
T41	Eq-Comparison 591 598	< 30 kg
E18	Eq-Comparison:T41 Operator:T18 Unit:T24 Value:T33
T42	Eq-Comparison 624 637	within 1 week
E19	Eq-Comparison:T42 Operator:T19 Value:T34 Temporal-Unit:T87
T43	Eq-Comparison 755 768	within 1 week
E20	Eq-Comparison:T43 Operator:T20 Value:T35 Temporal-Unit:T103
T44	Eq-Comparison 289 296	history
E21	Eq-Comparison:T44 Temporal-Period:T45
T45	Eq-Temporal-Period 289 296	history
A14	Eq-Temporal-Period-Value T45 past
T46	Eq-Comparison 774 781	History
E22	Eq-Comparison:T46 Temporal-Period:T47
T47	Eq-Temporal-Period 774 781	History
A15	Eq-Temporal-Period-Value T47 past
T48	Or 33 35	or
E2	Or:T48 Arg:T8 Arg2:T5
T14	Eq-Operator 57 59	to
A4	Eq-Operator-Value T14 BETWEEN
T21	Eq-Value 62 64	18
T27	Eq-Temporal-Unit 65 70	years
A11	Eq-Temporal-Unit-Value T27 year
T37	Condition 91 93	AD
E4	Condition:T37 Name:T49 Duration:E7
T49	Condition-Name 91 93	AD
T50	Modifier 83 90	Chronic
E5	Modifier:T50 Modifies:T49
T51	Eq-Comparison 123 139	at least 2 years
E7	Eq-Comparison:T51 Operator:T52 Value:T28 Temporal-Unit:T22
T52	Eq-Operator 123 131	at least
A16	Eq-Operator-Value T52 GTEQ
T6	Observation 145 175	Eczema Area and Severity Index
E6	Observation:T6 Name:T7
T7	Observation-Name 145 175	Eczema Area and Severity Index
A17	Observation-Type-Value T7 clinical-score
T53	Observation 177 181	EASI
E8	Observation:T53 Name:T54 Eq-Comparison:E15
T54	Observation-Name 177 181	EASI
R1	Abbrev-Of Arg1:E8 Arg2:E6	
T55	Observation 199 202	IGA
E10	Observation:T55 Name:T56 Eq-Comparison:E16
T56	Observation-Name 199 202	IGA
A18	Observation-Type-Value T56 clinical-score
T57	Observation 218 232	AD involvement
E14	Observation:T57 Name:T58 Eq-Comparison:E17
T58	Observation-Name 218 232	AD involvement
A19	Observation-Type-Value T58 measurement
T59	Eq-Unit 237 238	%
T60	Eq-Unit 242 259	Body Surface Area
T61	Eq-Unit 261 264	BSA
R2	Abbrev-Of Arg1:T61 Arg2:T60	
T62	Eq-Comparison 282 288	recent
E23	Eq-Comparison:T62 Temporal-Period:T63
T63	Eq-Temporal-Period 282 288	recent
A20	Eq-Temporal-Period-Value T63 recent
T64	Drug 323 342	topical medications
E24	Drug:T64 Name:T65 Temporality:E21 Temporality2:E23
T65	Drug-Name 323 342	topical medications
T66	Life-Stage-And-Gender 348 353	Women
A21	Life-Stage-And-Gender-Type T66 female
T67	Condition 357 369	childbearing
E25	Condition:T67 Name:T68
T68	Condition-Name 357 369	childbearing
R3	If-Then Arg1:T66 Arg2:E25	
T69	Assertion 370 379	potential
E26	Assertion:T69 Asserted:E25
A22	Assertion-Type-Value E26 hypothetical
T70	Condition 406 415	abstinent
E27	Condition:T70 Name:T71
T71	Condition-Name 406 415	abstinent
T72	Assertion 385 393	agree to
E28	Assertion:T72 Asserted:E27 Asserted2:E3
A23	Assertion-Type-Value E28 hypothetical
R4	If-Then Arg1:E25 Arg2:E27	
T73	Or 416 418	or
E29	Or:T73 Arg:E27 Arg2:E3
T74	Study 491 496	study
E30	Study:T74 
T75	Temporal-Connection 476 486	throughout
E31	Temporal-Connection:T75 Arg:E3 Arg2:E30
A24	Temporal-Connection-Type-Value E31 during
T76	Study 529 534	study
E32	Study:T76 Study-Of:E1
T77	Eq-Comparison 524 528	last
E33	Eq-Comparison:T77 Temporal-Recency:T78
T78	Eq-Temporal-Recency 524 528	last
A25	Eq-Temporal-Recency-Value T78 most-recent-time
T79	Temporal-Connection 514 519	after
E34	Temporal-Connection:T79 Arg:E35 Arg2:E33
A26	Temporal-Connection-Type-Value E34 after
T80	Eq-Comparison 505 513	12 weeks
E35	Eq-Comparison:T80 Value:T32 Temporal-Unit:T23
T81	And 497 500	and
E36	And:T81 Arg:E30 Arg2:E35
T82	Observation 579 590	Body weight
E37	Observation:T82 Name:T83 Eq-Comparison:E18
T83	Observation-Name 579 590	Body weight
A27	Observation-Type-Value T83 vital
T84	Condition 614 623	infection
E38	Condition:T84 Name:T85 Temporality:E19
T85	Condition-Name 614 623	infection
T86	Modifier 604 613	Cutaneous
E39	Modifier:T86 Modifies:T85
T87	Eq-Temporal-Unit 633 637	week
A28	Eq-Temporal-Unit-Value T87 week
T88	Condition 645 654	infection
E40	Condition:T88 Name:T89
T89	Condition-Name 645 654	infection
T90	Or 638 640	or
E41	Or:T90 Arg:E38 Arg2:E40
T91	Procedure 665 674	treatment
E42	Procedure:T91 
T92	Modifier 688 698	parenteral
E43	Modifier:T92 Modifies:T12
T93	Modifier 680 684	oral
E44	Modifier:T93 Modifies:T12
T94	Or 685 687	or
E45	Or:T94 Arg:E44 Arg2:E43
R5	Using Arg1:E42 Arg2:E11	
T95	Assertion 655 664	requiring
E46	Assertion:T95 Asserted:E42
A29	Assertion-Type-Value E46 hypothetical
R6	Treatment-For Arg1:E42 Arg2:E40	
T96	Drug 712 722	antivirals
E47	Drug:T96 Name:T97 Temporality:E20
T97	Drug-Name 712 722	antivirals
T98	Drug 724 738	antiparasitics
E48	Drug:T98 Name:T99 Temporality:E20
T99	Drug-Name 724 738	antiparasitics
T100	Drug 743 754	antifungals
E49	Drug:T100 Name:T101 Temporality:E20
T101	Drug-Name 743 754	antifungals
T102	Or 740 742	or
E50	Or:T102 Arg:E48 Arg2:E49
T103	Eq-Temporal-Unit 764 768	week
A30	Eq-Temporal-Unit-Value T103 week
T104	Condition 785 801	hypersensitivity
E51	Condition:T104 Name:T105 Temporality:E22
T105	Condition-Name 785 801	hypersensitivity
R7	Example-Of Arg1:E9 Arg2:E51	
T106	Drug 832 854	immunoglobulin product
E52	Drug:T106 Name:T107
T107	Drug-Name 832 854	immunoglobulin product
R8	Caused-By Arg1:E51 Arg2:E52	
T108	Drug 891 910	monoclonal antibody
E53	Drug:T108 Name:T109
T109	Drug-Name 891 910	monoclonal antibody
T110	Modifier 874 885	recombinant
E54	Modifier:T110 Modifies:T109
T111	Modifier 856 870	plasma-derived
E55	Modifier:T111 Modifies:T109
T112	Or 871 873	or
E56	Or:T112 Arg:E55 Arg2:E54
R9	Example-Of Arg1:E53 Arg2:E52	
T113	Condition 944 949	issue
E57	Condition:T113 Severity:T114
T114	Severity 932 943	significant
A31	Severity-Value T114 severe
